@article{KirstenOhmGehrdauetal.2022,
  author    = {Kirsten, Natalia and Ohm, Frenz and Gehrdau, Kathrin and Girbig, Gefion and Stephan, Brigitte and Ben-Anaya, Nesrine and Pinter, Andreas and Bechara, Falk G. and Presser, Dagmar and Zouboulis, Christos C. and Augustin, Matthias},
  title     = {Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest},
  series = {Life},
  volume    = {12},
  journal   = {Life},
  number    = {10},
  issn      = {2075-1729},
  doi       = {10.3390/life12101518},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-288213},
  year      = {2022},
  abstract  = {Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3\% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3\% (n = 19/31) experienced LoR but no AEs, 22.6\% (n = 7/31) LoR combined with AEs and 16.1\% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.},
  language  = {en}
}
@article{VaiopoulosKanakisKapsimalietal.2016,
  author    = {Vaiopoulos, Aristeidis G. and Kanakis, Meletios A. and Kapsimali, Violetta and Vaiopoulos, Georgios and Kaklamanis, Phedon G. and Zouboulis, Christos C.},
  title     = {Juvenile Adamantiades-Beh{\c{c}}et disease},
  series = {Dermatology},
  volume    = {232},
  journal   = {Dermatology},
  number    = {2},
  issn      = {1018-8665},
  doi       = {10.1159/000442667},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196616},
  pages     = {129 -- 136},
  year      = {2016},
  abstract  = {Adamantiades-Beh{\c{c}}et disease (ABD) is a chronic, multisystemic, recurrent, inflammatory vascular disorder of unknown etiology. Patients with symptoms initially appearing at the age of 16 or less are considered as cases of juvenile-onset ABD (JABD). JABD is relatively rare compared to ABD of adults, and only case reports and case studies have been published regarding this subtype of the disease. Epidemiology, clinical features, diagnosis and treatment of JABD are discussed in this review.},
  language  = {en}
}